troglitazone has been researched along with Hyperlipidemias in 20 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that the administration of troglitazone (TGZ), an insulin-sensitizing agent of the thiazolidinedione class, would improve dyslipidemia associated with insulin resistance in polycystic ovary syndrome (PCOS)." | 9.10 | Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| "Insulin resistance is thought to lead to overproduction of very low-density lipoprotein (VLDL) cholesterol through the decreased peripheral lipoprotein lipase (LPL) activity, increased production of apolipoprotein B-100 and decreased clearance of remnant particles." | 6.41 | [Dyslipidemia in insulin resistance and its improvement by troglitazone]. ( Mabuchi, H; Yagi, K, 2000) |
| "We hypothesized that the administration of troglitazone (TGZ), an insulin-sensitizing agent of the thiazolidinedione class, would improve dyslipidemia associated with insulin resistance in polycystic ovary syndrome (PCOS)." | 5.10 | Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| "Troglitazone, a newly introduced insulin sensitizer, has been implicated in prevention and treatment of atherosclerotic cardiovascular disease especially associated with type 2 diabetes mellitus and insulin resistance." | 4.80 | [Cardiovascular effects of the thiazolidinedione troglitazone]. ( Kuzuya, H; Nakano, T; Yamada, K, 2000) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| "Insulin resistance is thought to lead to overproduction of very low-density lipoprotein (VLDL) cholesterol through the decreased peripheral lipoprotein lipase (LPL) activity, increased production of apolipoprotein B-100 and decreased clearance of remnant particles." | 2.41 | [Dyslipidemia in insulin resistance and its improvement by troglitazone]. ( Mabuchi, H; Yagi, K, 2000) |
| "Insulin resistance is known to unite several metabolic abnormalities." | 2.41 | Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. ( Daida, H; Sunayama, S; Watanabe, Y; Yamaguchi, H, 2000) |
| "Troglitazone is a CYP3A4 isoenzyme inducer known to decrease the plasma concentration of drugs metabolized by CYP3A4." | 1.31 | Potential interaction between troglitazone and atorvastatin. ( DiTusa, L; Luzier, AB, 2000) |
| "Troglitazone has been shown to improve insulin sensitivity and thereby exert hypoglycemic effects in various animal models and humans with insulin resistance and diabetes." | 1.31 | Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. ( Akiyama, T; Fukumitsu, KI; Jia, DM; Nakamura, H; Otsuki, M; Tabaru, A, 2000) |
| "Troglitazone is a newly developed antidiabetic drug and is indicated to be useful for the treatment of patients with type II diabetes mellitus." | 1.31 | Troglitazone prevents fatty changes of the liver in obese diabetic rats. ( Abe, S; Akiyama, T; Jia, DM; Otsuki, M; Tabaru, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 14 (70.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Legro, RS | 1 |
| Azziz, R | 1 |
| Ehrmann, D | 1 |
| Fereshetian, AG | 1 |
| O'Keefe, M | 1 |
| Ghazzi, MN | 1 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Katayama, S | 1 |
| Saku, K | 1 |
| Zhang, B | 1 |
| Ohta, T | 1 |
| Arakawa, K | 1 |
| Howard, BV | 1 |
| Howard, WJ | 1 |
| Granberry, MC | 1 |
| Fonseca, VA | 1 |
| Kobayashi, J | 1 |
| Nagashima, I | 1 |
| Hikita, M | 1 |
| Bujo, H | 1 |
| Takahashi, K | 1 |
| Otabe, M | 1 |
| Morisaki, N | 1 |
| Saito, Y | 1 |
| Ginsberg, H | 1 |
| Plutzky, J | 1 |
| Sobel, BE | 1 |
| Booth, AM | 1 |
| Caldwell, SH | 1 |
| Iezzoni, JC | 1 |
| Yagi, K | 1 |
| Mabuchi, H | 1 |
| Iwatani, M | 1 |
| Wasada, T | 1 |
| Iwamoto, Y | 1 |
| Kamatani, N | 1 |
| Yamada, K | 1 |
| Kuzuya, H | 1 |
| Nakano, T | 1 |
| Kadowaki, T | 1 |
| Sunayama, S | 1 |
| Watanabe, Y | 1 |
| Daida, H | 1 |
| Yamaguchi, H | 1 |
| DiTusa, L | 1 |
| Luzier, AB | 1 |
| Jia, DM | 2 |
| Tabaru, A | 2 |
| Nakamura, H | 1 |
| Fukumitsu, KI | 1 |
| Akiyama, T | 2 |
| Otsuki, M | 2 |
| Abe, S | 1 |
| Marcus, AO | 1 |
| Nakamura, T | 1 |
| Funahashi, T | 1 |
| Yamashita, S | 1 |
| Nishida, M | 1 |
| Nishida, Y | 1 |
| Takahashi, M | 1 |
| Hotta, K | 1 |
| Kuriyama, H | 1 |
| Kihara, S | 1 |
| Ohuchi, N | 1 |
| Nishimura, T | 1 |
| Kishino, BI | 1 |
| Ishikawa, K | 1 |
| Kawamoto, T | 1 |
| Tokunaga, K | 1 |
| Nakagawa, C | 1 |
| Mineo, I | 1 |
| Watanabe, F | 1 |
| Tarui, S | 1 |
| Matsuzawa, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring[NCT00290394] | Phase 4 | 25 participants | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for troglitazone and Hyperlipidemias
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
Topics: Antioxidants; Blood Coagulation; Cardiovascular Diseases; Cardiovascular System; Cholesterol, LDL; C | 1999 |
[Dyslipidemia in insulin resistance and its improvement by troglitazone].
Topics: Cholesterol, HDL; Chromans; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Thiazo | 2000 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; H | 2000 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellit | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.
Topics: Chromans; Clinical Trials as Topic; Glucose; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin R | 2000 |
Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
Topics: Acarbose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human | 2000 |
2 trials available for troglitazone and Hyperlipidemias
| Article | Year |
|---|---|
Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Chromans; Female; Humans; Hyperlipidemias; Hypoglycemic A | 2003 |
Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.
Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Body Composition; Cholesterol; Chromans; Double-Blind | 2001 |
7 other studies available for troglitazone and Hyperlipidemias
| Article | Year |
|---|---|
Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Blood Pressure; Chromans; Female; Heart Rate; Hyperlipidemias; Insulin; Insulin Resistance; | 1997 |
LDL cholesterol and troglitazone therapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Hu | 1998 |
Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase.
Topics: 3T3 Cells; Adipocytes; Aged; Animals; Blood Glucose; Blotting, Northern; Chromans; Diabetes Mellitus | 1999 |
Troglitazone-associated hepatic failure.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Fe | 2000 |
Potential interaction between troglitazone and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Chromans; Diabetes Mellitus; Drug In | 2000 |
Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus | 2000 |
Troglitazone prevents fatty changes of the liver in obese diabetic rats.
Topics: Age Factors; Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; | 2000 |